Biocon Biologics

Bangalore, IN
Cell Therapy
Program data pending ClinicalTrials.gov matching · Last scored 2026-03-15
60.5
Signal Score
✓ FDA Inspections (2) ○ Clinical Trials ○ SEC Filings ✓ Press (3)

Quick Facts: Biocon Biologics

Signal Score
60.5/100 (as of 2026-03-15)
Quality Compliance
Assessment pending
Headquarters
Bangalore, IN
Modalities
Cell Therapy
Active CGT Programs
No ClinicalTrials.gov matches confirmed
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CGT manufacturing intelligence platform

Signal Score & Pillar Breakdown

Quality Compliance —
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA Inspections2 on record
Warning Letters0
Last InspectionVoluntary Action Indicated (VAI) (2025-09-03)
Operations —
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs — no verified data
Sponsors— no verified data
ModalitiesCell Therapy
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability 68.0
Parent company: Biocon
Financial assessment: 68.0/100
Source: SEC EDGAR, press monitoring
Subsidiary of Biocon
SEC FilingsParent: Biocon
Parent company: Biocon
Financial assessment: 68.0/100
Capacity 53.0
1 CGT manufacturing site: Bangalore, IN
Modalities: Cell Therapy
Capacity assessment: 53.0/100
Sites: Bangalore, IN
Source: SEC EDGAR, press monitoring, company profiles
1 CGT manufacturing site
Recent Press3 articles
1 CGT manufacturing site: Bangalore, IN
Modalities: Cell Therapy
Capacity assessment: 53.0/100

FDA Inspection History

2025-09
2024-07
NAI VAI OAI
Date Site Type Observations Classification
2025-09-03 Bengaluru Drug Quality Assurance No Voluntary Action Indicated (VAI)
2024-07-26 Bengaluru Drug Quality Assurance No Voluntary Action Indicated (VAI)
Source: FDA Data Dashboard · Retrieved Mar 20, 2026

Recent News 3 articles

general 2026-03-12
Biologics Market Trends: Monoclonal Antibodies, Biosimilars Growth & Forecast to 2034 - vocal.media
Biologics Market Trends: Monoclonal Antibodies, Biosimilars Growth & Forecast to 2034  vocal.media
Source →
general 2026-02-27
Blue Jet Pharma Expands: $300M Facility Targets CDMO Growth - Whalesbook
Blue Jet Pharma Expands: $300M Facility Targets CDMO Growth  Whalesbook
Source →
general 2026-02-16
Top 10 Gene Editing Companies In 2026 - inventiva.co.in
Top 10 Gene Editing Companies In 2026  inventiva.co.in
Source →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Cell Therapy CDMOs →